Rwanda

The Rwanda Food and Drugs Authority (FDA Rwanda), established under Law No. 60/2018 of 22/08/2018 governing the regulation of food, drugs, and other regulated products and services, serves as the primary national regulatory authority overseeing health products including pharmaceuticals, medical devices, diagnostics, and digital health solutions. FDA Rwanda operates under the Ministry of Health and is responsible for product registration, market surveillance, licensing of manufacturers and distributors, and post-market controls. All health products intended for the Rwandan market must obtain marketing authorization from FDA Rwanda prior to importation, distribution, or sale, with the review process involving technical dossier evaluation, facility inspections where applicable, and safety and quality assessments.

Applicants are required to appoint a local authorized representative registered in Rwanda to submit and manage product dossiers. FDA Rwanda accepts dossiers aligned with the Common Technical Document (CTD) format and is increasingly harmonized with the East African Community (EAC) regional regulatory framework, including participation in the EAC Medicines Registration Harmonization (MRH) initiative. Rwanda is also a member of the African Medicines Regulatory Harmonization (AMRH) program and recognizes approvals from stringent regulatory authorities (SRAs) such as the US FDA, EMA, and Health Canada, which can expedite review timelines. Recent reforms have focused on strengthening pharmacovigilance systems, introducing risk-based regulatory pathways, and advancing e-submission platforms to improve efficiency and transparency in the registration process.

Public procurement of health products in Rwanda is centrally coordinated through the Ministry of Health (MoH) in partnership with the Rwanda Medical Supply (RMS) Limited, a government-owned entity responsible for the quantification, procurement, warehousing, and distribution of medicines, medical devices, and diagnostics across the public health system. National tenders are governed by the Rwanda Public Procurement Authority (RPPA) under Law No. 17/2016 of 26/04/2016 on public procurement, which mandates competitive bidding processes, transparency requirements, and value-for-money assessments. Health facilities, including district hospitals and health centers, are supplied through the RMS distribution network, with facility-level needs consolidated through the national quantification process aligned with Rwanda's Health Sector Strategic Plan.

The private sector plays a complementary role, with products distributed through licensed pharmaceutical wholesalers and retail pharmacies operating under FDA Rwanda oversight. Rwanda benefits significantly from donor-funded procurement channels, including the Global Fund to Fight AIDS, Tuberculosis and Malaria, USAID through its implementing partners (such as PEPFAR-funded programs), UNICEF, and Gavi, the Vaccine Alliance, which collectively support procurement of essential medicines, vaccines, diagnostics, and health commodities outside of direct government budget channels. While Rwanda does not yet enforce formal local manufacturing preference policies, the government actively supports regional manufacturing development through the EAC framework and has expressed strategic intent to increase domestic pharmaceutical production capacity as part of its broader health sector self-reliance agenda.